Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMBISOME vs GYNIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
Empirical therapy for presumed fungal infection in febrile neutropenic patients,Treatment of cryptococcal meningitis in HIV-infected patients,Treatment of visceral leishmaniasis,Treatment of invasive aspergillosis (alternate therapy),Treatment of candidiasis (invasive and mucosal),Treatment of histoplasmosis (severe disseminated),Treatment of blastomycosis (severe),Treatment of coccidioidomycosis (severe),Treatment of mucormycosis,Treatment of fusariosis,Treatment of talaromycosis (penicilliosis)
Cervical inflammation,Vaginal infections,Treatment of genital warts,Chemical cautery of skin lesions
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 12-15 hours in severe renal impairment (Cr Cl <30 m L/min).
Amphotericin B is predominantly cleared via the reticuloendothelial system and is excreted slowly in urine and feces. Metabolism is not well characterized, but it is not extensively metabolized by liver enzymes.
Not metabolized; acts locally via direct chemical action.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%.
Highly bound (>90%), primarily to albumin and alpha-1-acid glycoprotein.
Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein.
Vd: 0.4–0.6 L/kg; reflects extensive tissue distribution, particularly into organs of the reticuloendothelial system (liver, spleen).
Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone).
Intravenous: 100% (only route of administration).
Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%.
No dose adjustment required for renal impairment; use caution in patients with pre-existing renal disease and monitor renal function.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min: use with caution, consider alternative therapy.
No specific dose adjustment for Child-Pugh class A or B; for Child-Pugh class C, consider dose reduction or increased monitoring due to potential hepatotoxicity.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated.
For systemic fungal infections: 3-5 mg/kg/day IV; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21; weight-based dosing with no maximum daily dose specified.
Not approved for use in pediatric patients.
No specific dose adjustment; monitor renal function closely due to age-related decreased GFR and potential nephrotoxicity.
No dose adjustment required; use same as adult dosing.
Amphotericin B products should be used primarily for treatment of severe fungal infections in immunocompromised patients where significant toxicity is justified. Amphotericin B is associated with severe nephrotoxicity, especially when used at higher doses or with other nephrotoxic agents. Infusion-related reactions (fever, chills, rigors, hypotension) are common and may be severe.
None.
Nephrotoxicity: Monitor renal function closely; avoid concomitant nephrotoxic drugs when possible.,Infusion reactions: Premedication (e.g., acetaminophen, antihistamines, corticosteroids) may reduce severity.,Electrolyte disturbances: Hypokalemia, hypomagnesemia may occur; monitor and replace as needed.,Hepatotoxicity: Monitor liver function tests.,Cardiotoxicity: Rarely associated with arrhythmias; caution in patients with cardiac disease.,Pancreatitis: Has been reported; consider in patients with abdominal pain.
Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions.
Hypersensitivity to amphotericin B or any component of the formulation (unless the condition is life-threatening and amenable only to amphotericin B therapy)
Hypersensitivity to trichloroacetic acid; pregnancy (relative); use on malignant tissue.
No known significant food interactions. Grapefruit juice does not affect liposomal amphotericin B metabolism.
No known food interactions with topical use. However, avoid concurrent use of iodine-containing supplements or medications, as it may increase systemic iodine load.
Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no known fetal risks.
First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal.
Excretion in human milk unknown; caution advised. M/P ratio not available.
No data on excretion in human milk. Expected minimal systemic absorption. Use caution if applied to breast area. M/P ratio unknown.
No dose adjustment required for systemic exposure in pregnancy; pharmacokinetic changes not significant.
No dose adjustment necessary for topical use. Systemic absorption negligible.
Am Bisome (liposomal amphotericin B) is preferred over conventional amphotericin B due to reduced nephrotoxicity and infusion-related reactions. Dose adjustment not required in renal impairment, but monitor renal function closely. Premedication with acetaminophen, diphenhydramine, and hydrocortisone may reduce infusion reactions. For cryptococcal meningitis in HIV, combination with flucytosine is recommended. Not interchangeable with other amphotericin B formulations; verify dose and product before administration.
GYNIX (povidone-iodine) is a topical antiseptic. Avoid use in patients with iodine hypersensitivity or thyroid disorders (e.g., Hashimoto's thyroiditis). Prolonged use on large wounds may cause iodine absorption and thyroid dysfunction. Monitor for local irritation or allergic contact dermatitis.
Take exactly as prescribed; do not skip doses or stop early.,Infusion reactions (fever, chills, nausea) may occur; report these to your healthcare provider.,Drink plenty of fluids unless advised otherwise by your doctor.,Contact your doctor immediately if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Tell your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements.,This medication can cause kidney problems; you will need regular blood tests.
Do not use if you are allergic to iodine or have a thyroid condition.,For external use only. Avoid contact with eyes, mouth, or open wounds unless directed.,Discontinue and inform your doctor if you develop rash, itching, or swelling.,Store at room temperature away from light. Do not freeze or heat.,Not for use on deep or puncture wounds, or severe burns without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMBISOME vs GYNIX, answered by our medical review team.
AMBISOME is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.. GYNIX is a Polyene Antifungal that works by Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMBISOME and GYNIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMBISOME is: 3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.. The standard adult dose of GYNIX is: 1 vaginal tablet (100 mg) once daily at bedtime for 7 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMBISOME and GYNIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMBISOME is classified as Category C. Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no . GYNIX is classified as Category C. First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.